The average price suggested by analysts for FULC is $10.21, which is $5.56 above the current market price. The public float for FULC is 58.13M, and currently, shorts hold a 6.80% of that float. The average trading volume for FULC on November 21, 2023 was 1.99M shares.
FULC) stock’s latest price update
Fulcrum Therapeutics Inc (NASDAQ: FULC)’s stock price has gone rise by 12.05 in comparison to its previous close of 4.15, however, the company has experienced a 34.01% increase in its stock price over the last five trading days. GlobeNewsWire reported 2023-11-09 that CAMBRIDGE, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) — Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that management will participate in the following upcoming investor conferences:
FULC’s Market Performance
FULC’s stock has risen by 34.01% in the past week, with a monthly rise of 27.75% and a quarterly drop of -14.36%. The volatility ratio for the week is 9.69% while the volatility levels for the last 30 days are 9.23% for Fulcrum Therapeutics Inc The simple moving average for the past 20 days is 26.05% for FULC’s stock, with a 5.50% simple moving average for the past 200 days.
Analysts’ Opinion of FULC
Many brokerage firms have already submitted their reports for FULC stocks, with Goldman repeating the rating for FULC by listing it as a “Neutral.” The predicted price for FULC in the upcoming period, according to Goldman is $5 based on the research report published on September 25, 2023 of the current year 2023.
FULC Trading at 16.02% from the 50-Day Moving Average
After a stumble in the market that brought FULC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -69.00% of loss for the given period.
Volatility was left at 9.23%, however, over the last 30 days, the volatility rate increased by 9.69%, as shares surge +31.73% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -12.76% lower at present.
During the last 5 trading sessions, FULC rose by +34.01%, which changed the moving average for the period of 200-days by -63.18% in comparison to the 20-day moving average, which settled at $3.74. In addition, Fulcrum Therapeutics Inc saw -36.13% in overturn over a single year, with a tendency to cut further losses.
Reports are indicating that there were more than several insider trading activities at FULC starting from Tourangeau Greg, who sale 210 shares at the price of $3.31 back on May 10. After this action, Tourangeau Greg now owns 15,992 shares of Fulcrum Therapeutics Inc, valued at $695 using the latest closing price.
RA CAPITAL MANAGEMENT, L.P., the 10% Owner of Fulcrum Therapeutics Inc, purchase 1,923,076 shares at $13.00 during a trade that took place back on Jan 20, which means that RA CAPITAL MANAGEMENT, L.P. is holding 11,609,704 shares at $24,999,988 based on the most recent closing price.
Stock Fundamentals for FULC
Current profitability levels for the company are sitting at:
- -1768.12 for the present operating margin
- +61.94 for the gross margin
The net margin for Fulcrum Therapeutics Inc stands at -1732.43. The total capital return value is set at -52.91, while invested capital returns managed to touch -52.16. Equity return is now at value -41.40, with -37.49 for asset returns.
Based on Fulcrum Therapeutics Inc (FULC), the company’s capital structure generated 6.75 points at debt to equity in total, while total debt to capital is 6.32. Total debt to assets is 5.92, with long-term debt to equity ratio resting at 5.44. Finally, the long-term debt to capital ratio is 5.10.
When we switch over and look at the enterprise to sales, we see a ratio of 25.61, with the company’s debt to enterprise value settled at 0.10. The receivables turnover for the company is 2.44 and the total asset turnover is 0.03. The liquidity ratio also appears to be rather interesting for investors as it stands at 12.41.
In conclusion, Fulcrum Therapeutics Inc (FULC) has had a mixed performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.